Cargando…
Acute Pancreatitis in a Previously Exocrine Pancreatic Insufficient Cystic Fibrosis Patient Who Had Improved Pancreatic Function After Being Treated With Lumacaftor/Ivacaftor
Exocrine pancreatic insufficiency (EPI) is a common complication of cystic fibrosis (CF). While previously considered to be irreversible, recent reported cases document improved pancreatic function in CF patients with mild mutations after ivacaftor treatment alone. We report a 12-year-old female wit...
Autores principales: | Redman, Alexander W., Yoo, Michelle, Freswick, Peter, Thompson, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191563/ https://www.ncbi.nlm.nih.gov/pubmed/37205952 http://dx.doi.org/10.1097/PG9.0000000000000096 |
Ejemplares similares
-
Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022) -
Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020) -
Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022) -
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021)